Comparative Pharmacology
Head-to-head clinical analysis: RETACRIT versus VAFSEO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RETACRIT versus VAFSEO.
RETACRIT vs VAFSEO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RETACRIT (epoetin alfa-epbx) is a recombinant human erythropoietin that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.
VAFSEO (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-α, leading to increased transcription of genes involved in erythropoiesis, including erythropoietin, enhancing red blood cell production.
50-100 IU/kg intravenously or subcutaneously three times weekly; initial dose 50 IU/kg three times weekly, titrated to target hemoglobin 10-12 g/dL.
Oral: 20 mg three times weekly for 24 weeks.
None Documented
None Documented
Terminal elimination half-life is ~2.5-4.5 hours following intravenous administration; shorter in children; prolonged in hepatic impairment.
Terminal half-life is approximately 20-30 hours, supporting once-daily dosing.
Primarily hepatic metabolism; ~10% excreted unchanged in urine, remainder via feces as metabolites.
Primarily fecal (approximately 81%) and renal (~17%) as unchanged drug and metabolites.
Category C
Category C
Erythropoiesis-Stimulating Agent
Erythropoiesis-Stimulating Agent